Pharmacovigilance and Pharmacoepidemiology (ISSN: 2638-8235)

About Journal

Pharmacovigilance is a study of science which deals with the assessment, detection, collection, understanding and prevention of adverse side effects in medical and drug therapies. This is helpful to prevent the ill-favored suffering by the patients in order to reduce the financial loss which is sustained by the patients due to inappropriate and unsafe use of medicine. This is also known as Drug Safety. Pharmacovigilance Journal discusses the latest research innovations and important developments in this field. Pharmacovigilance Journal is interested in the special fields related to the topics of this Journal.

Pharmacoepidemiology is the study of use and effects of drugs among the large number of people. The term Pharmacoepidemiology involves both the pharmacology and epidemiology. The pharmacology is related to the effect of drugs in humans, while epidemiology deals with the factors which determine the occurrence and distribution of diseases in population. Pharmacovigilance and Pharmacoepidemiology Journal offer a stage in Pharmacoepidemiology Researches and related subjects. Journal accepts leading forefront original research papers, review manuscripts, case reports and commentary in the field. Our target audience, readers and contributors are worldwide. Pharmacoepidemiology Researches invites an article to publish in the Journal of Pharmacovigilance and Pharmacoepidemiology. Pharmacovigilance and Pharmacoepidemiology is a scholarly journal maintaining high standards of Pharmacoepidemiology Researches. This Journal runs with scientific excellence and propagates the peer review process very quickly.

Indexing and Archiving

Current Issues

Editorial Board Members

The Journal of Pharmacovigilance and Pharmacoepidemiology is having the editorial members globally

  •  Hamid Omidian is a Professor in Nova Southeastern University from United States.
  •  Peter Little is a Professor in University of Queensland from Australia
  •  Zhi Ling Yu is an Associate Director in Hong Kong Baptist University from Hong Kong
  •  Mario Giorgi is an Associate Professor in the Department of Veterinary Sciences from the University of Pisa, Italy
  •  Erini Serag-Bolos is an Assistant Professor in the Department of Pharmacotherapeutics  and Clinical Research Department from the University of South Florida, USA

For more information on EB visit Editorial Page

The Scope the Journal

The aim of the Journal is to publish high quality research in the discipline of Pharmacovigilance by providing encouragement for editors, reviewers, authors, and readers to have an uninterrupted scientific communication.

This Journal accepts articles from different disciplines as below but not constrained to only these Pharmacovigilance signal, Pharmacovigilance data management, Design and development of drug, Principles of Pharmacology, quality system and Pharmacovigilance, Pharmacovigilance softwares, Drug regulatory activities, Drug reactions and diagnosis, Reporting systems, Clinical trials and Pharmacovigilance, Marketing surveillance, Pharmacovigilance ethics and regulations, Biomarkers and Pharmacology, concepts and trends in Pharmacovigilance, Pharmaceutical medicines, Drug delivery systems, Statistics and data management. Edelweiss publications include rigorous peer review process and high scientific publishing standard to ensure superior contribution to scholarly literature added with high quality production.

The focused topics are:

Pharmacovigilance and Pharmacoepidemiology welcome Submissions related to above fields. Authors may submit their valuable work at


Pharmacokinetics is a branch of pharmacology which deals with the movement of drug in the living organisms. The substance which includes any chemical xenobiotic such as pesticides, cosmetics, pharmaceutical drugs, food additives etc. It analyze the chemical metabolism, discover the fate of a chemical, act accordingly and the drug is excreted from the body. We at Edelweiss publications support the researches that work and publish the manuscripts on Pharmacokinetics. Pharmacokinetics articles invite all the topics related to the Pharmacokinetics. We publish the peer reviewed articles with innovational work on the topic of Pharmacokinetics articles. This Journal accepts leading forefront original research papers, review manuscripts, case reports and commentary in the field. Our target audience, readers and contributors are worldwide. Pharmacovigilance and Pharmacoepidemiology offer a stage for Pharmacokinetics articles.

The criteria of a drug

  • Absorption – is the process in which the drug enters into the body and absorbed.
  • Distribution – the drug rapidly circulates into the blood after the absorption, later the drug moves into the body tissues from the blood.
  • Metabolism – Drug can be metabolized by reduction, oxidation, hydration, conjugation, hydrolysis and condensation. The main goal of drug is to eliminate from the body easily. The metabolism differs from person to person, genetic factors influence the rate of the drug metabolism individually.
  • Excretion – is a process in which the drug must be removed from the body. In some cases, the drug accumulates the body tissue which may cause side effects.


Journal of Pharmacovigilance and Pharmacoepidemiology welcomes research on Pharmacodynamics. Pharmacodynamics is a study which deals with the physiologic and biochemical effects of drugs. This is about how a drug affects an organism, while the pharmacokinetics is how the organism affects the drug. Both of them influence benefit, dosing and adverse effect. A drugs physiologic changes affected by the pharmacodynamics are due to the aging and disorder. Aging leads to affect pharmacodynamics response through alterations in receptor binding and the disorder effects of pharmacodynamics responses which involve thyrotoxicosis, myasthenia gravis, malnutrition, genetic mutations, Parkinson disease, myasthenia and some forms of insulin-resistant diabetes mellitus. These disorders can alter the level of binding proteins and also can change the receptor binding.

Drug discovery

Drug discovery is a process in which a new drug is designed and developed. Generally a drug is discovered based on the knowledge of properties such as molecular geometry, activity of functional groups and electronic structure. During the drug discovery dosage analysis and pharmacokinetics are not included. Edelweiss Publication Inc maintains the journal and promotes it around the globe and running this journal since three years and looking to propagate this journal among the researchers. Pharmacovigilance and Pharmacoepidemiology Journal provide a platform to put forth the ongoing research, review, and commentaries on Drug discovery Researches. Pharmacovigilance and Pharmacoepidemiology Journal is an OpenAccess peer reviewed scientific publication encompasses the wide range of Drug discovery Researches. Edelweiss Publications is running this journal since three years and looking to propagate this journal among the researchers around the globe.

Adverse drug reaction

The adverse drug is a reaction which is caused after the medication. This may occur when the medicine is of more dosage or combination of two or more drugs. Adverse drug reaction may also depend on patients immune system. Editorial Board has supported us to take this journal to new heights. We have rapid peer review process as this is done by editorial board members who are experts in the field. At Edelweiss Publication the journal editorial board members are given complete freedom and ask them to work with great zeal and publish the manuscripts which are good at research and introducing new techniques to world.


Toxicology deals with the adverse effects of chemical substances on living organisms. The relationship between the concentration of the drug and how it effects on the organism is of high importance in toxicology. The factors which influence the chemical toxicology include the route of exposure, dosage, gender, age and environment. We at Journal Pharmacovigilance and Pharmacoepidemiology welcomes case reports, review articles and research articles on toxicology. Edelweiss Publication will be glad to promote these researches and researchers worldwide.

Clinical Pharmacology

This is the study of the clinical use and the drugs, which connects the gap between the laboratory science and the medical practice. The main objective of clinical pharmacology is to promote the safety prescription, minimize the side effects and maximize the drug effects. Clinical Pharmacologists are pharmacists, scientists, and physicians whose focus in developing and understanding the new drug therapies. Clinical pharmacologists work in a variety of settings in industry, government and academia. Journal of Pharmacovigilance and Pharmacoepidemiology will be glad to publish the new methods involving in Clinical Pharmacology researchers all around the world can publish their new finding on this topic. Edelweiss Publications runs this Journal. Pharmacovigilance and Pharmacoepidemiology Journal invite researches to publish new methods on Pharmacology articles. The Pharmacology articles undergo rapid peer review process. We try to publish the manuscript within 4-6 weeks after submission.

Environmental pharmacology

Environmental pharmacology is emerging specialty of pharmacology it includes the study of interaction of drug with environment, gene with environment, toxin with environment and the  effects on ecosystem. Journal of Pharmacovigilance and Pharmacoepidemiology like to have research/review/case reports related to Environment Pharmacology, we at edelweiss publications make sure your articles reach worldwide by depositing it in different repositories and servers around the world, also get index in different indexing sites. All the Pharmacology articles are published in the Journal of Pharmacovigilance and Pharmacoepidemiology.

Medicinal Chemistry

Medicinal chemistry is concerned with the development, design and the synthesis of pharmaceutical drugs. The chemist and pharmacologist identify, synthesize the chemical agents that have a therapeutic action and evaluate the properties of existing drugs. The compounds used for the synthesis and design involves organic compounds such as atorvastatin, clopidogrel and fluticasone, biological such as, insulin glargine, erythropoietin and medicinal preparations such as recombinant proteins such as hormones, antibodies are useful as drugs. Journal of Pharmacovigilance and Pharmacoepidemiology covers the area of Medicinal Chemistry, all the research and reviews related to this topic is encouraged to be published in our journal.

Few Articles Published

D-Cell  Hypothesis  (Trace  Amine  Hypothesis)  of  Schizophrenia,  and importance of Trace Amine-Associated Receptor, Type 1 (TAAR1)

Author: Keiko Ikemoto

Abstract: Mesolimbic dopamine (DA) hyperactivity is a well-known pathophysiological hypothesis of schizophrenia. The author shows a hypothesis to clarify the molecular basis of mesolimbic DA hyperactivity of schizophrenia. An immunohistochemical method was used to show D-neuron (trace amine (TA) neuron) decrease in the nucleus accumbens (Acc) of postmortem brains with schizophrenia. The striatal D-neuron decrease in schizophrenia and consequent (TAAR1) stimulation decrease onto terminals of midbrain ventral tegmental area (VTA) DA neurons induces mesolimbic DA hyperactivity of schizophrenia. Dysfunction of subventricular neural stem cells (NSC), located partially overlapping Acc is the cause of D-neuron decrease in Acc. DA hyperactivity, which inhibits NSC proliferation, causes disease progression of schizophrenia. The highlight is the rational that the D-cell hypothesis (TA hypothesis) of schizophrenia is a pivotal theory to link NSC dysfunction hypothesis to DA hypothesis. From a therapeutic direction, (1) TAAR1 agonists, (2) DA D2 antagonists, and (3) neurotrophic substances have potential to normalize mesolimbic DA hyperactivity. To develop novel therapeutic strategies, metabolisms of TAAR1 ligands, and NSC- and D-neuron-pathophysiology of neuropsychiatric illnesses should further be explored.

Clinical Particularities  of  Drug-Induced Agranulocytosis or Severe Neutropenia in Elderly Patients

Author(s): Emmanuel Andrès, Rachel Cottet Mourot, Olivier Keller, Khalid Serraj and Thomas Vogel

Abstract: Agranulocytosis is a life-threatening disorder in any age and also in the elderly subjects who are receiving on the average a larger number of drugs than younger subjects. This disorder frequently occurs as an adverse reaction to drugs, particularly to antibiotics, antiplatelet agents, antithyroid drugs, neuroleptics or anti-epileptic agents and nonsteroidal anti-inflammatory agents. Although patients experiencing drug-induced agranulocytosis may initially be asymptomatic, the severity of the neutropenia usually translates into the onset of severe sepsis that requires intravenous broad-spectrum antibiotherapy. In this setting, hematopoietic growth factors have been shown to shorten the duration of neutropenia. Thus with appropriate management, the mortality rate of idiosyncratic drug-induced agranulocytosis is now of 5 to 10%. Today, drug-induced agranulocytosis still remains a rare event with an annual incidence from 3 to 12 cases per millions of people. However, given the increased life expectancy and subsequent longer exposure to drugs, as well as the development of new agents, physicians should be aware of this complication and its management.

Preclinical Toxicity Studies-Tool of Drug Discovery

Author(s): N.Venkatesan and M. Ramanathan

Abstract: As per WHO Drug is any substance or product that is used or is intended to be used to modify or explore physiological systems or pathological states for the benefit of the recipient. Hence the prime objective of using any substance as a drug is that it must be beneficial for the humans. A large number of compounds are synthesized every year but they cannot be directly used in humans as drugs because no one knows or can predict the possible harmful effects of these compounds in humans. That is why to explore the complete pharmacological profile of these compounds and to ensure complete human safety they are first tested on animals before clinical use. Preclinical Studies thus can be defined as Testing the newly discovered compound in animals with the objective of gaining information regarding the various aspects of the compound with respect to the biological systems so that the same can be extrapolated for the use of that compound in humans. As the evaluation progresses undesirable compounds gets rejected at each step, so that only a few out of thousands reach the stage when administration to the humans is considered.

Variable Responses to Vitamin-D Dosing

Author(s): Gokhale SG and Gokhale Sankalp

Introduction: Vitamin D deficiency is recognized as a global public health problem, with deficiency states reported from various countries. Acting as a Pro- Hormone; this is a unique endogenously synthesized vitamin. Besides its pivotal role in calcium homeostasis and bone mineral metabolism, the vitamin-D endocrine system is now recognized to sub-serve a wide range of fundamental biological functions in cell differentiation, inhibition of cell growth, and immunomodulation. Vitamin-D deficiency affects not only musculoskeletal health but also a wide range of acute and chronic disease. The metabolic product of vitamin-D is a potent, pleiotropic, repair and maintenance; secosteroid hormone that targets more than 200 human genes in a wide variety of tissues, meaning it has as many mechanisms of action on genes it targets. Two related sterol compounds viz. Cholecalciferol [Vitamin-D3] and Ergocalciferol [Vitamin-D2] are grouped as Vitamin-D. Cholecalciferol is of animal origin and the other Ergocalciferol [Vitamin-D2] is plant based. Interestingly, antirachitic properties of Vitamin-D2 and D3 are identical. After oral administration; Vitamin-D3 is absorbed better than D2 in small intestine; and bile is essential for absorption.



to get latest updates.

  Life Science

  Health Science

  Chemical Science